Yuan Yang, Peizhi Zhou, Maling Gou, Wu Lang, Yunhe Mao, Xiang Wang, Qing Mao, Yanhui Liu, Ruofei Liang, Jiewen Luo
Department of Neurosurgery, West China Hospital, Sichuan University, 37 Waiguoxuexiang, Chengdu 610041, China.
National Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
J Clin Neurosci. 2015 Aug;22(8):1227-31. doi: 10.1016/j.jocn.2015.01.025. Epub 2015 Jun 6.
We conducted a meta-analysis to comprehensively evaluate the current data on the overall efficacy of levetiracetam (LEV), a new generation antiepileptic drug, in patients with brain tumors. The efficacy of LEV in patients diagnosed with brain tumors has been evaluated in several studies, however, with inconsistent results. Bibliographic searches of the EMBASE, MEDLINE, ClinicalTrials.gov and Cochrane Central Register of the Controlled Trials databases were performed to identify articles and conference abstracts that investigated the efficacy of LEV in the treatment of brain tumor patients. Fourteen studies were included in this meta-analysis. Among the 14 included studies, two were randomized controlled trials. The subgroup analysis demonstrated that the complete response rate of LEV was 94% during the postoperative period and 84% during the long-term follow-up period. Our results suggest that LEV is a relatively effective drug for the treatment of brain tumor patients and its efficacy is slightly lower during the long-term follow-up period than during the postoperative period. Further randomized controlled trials are warranted.
我们进行了一项荟萃分析，以全面评估新一代抗癫痫药物左乙拉西坦（LEV）对脑肿瘤患者的总体疗效的现有数据。多项研究评估了LEV对诊断为脑肿瘤患者的疗效，但结果并不一致。我们检索了EMBASE、MEDLINE、ClinicalTrials.gov和Cochrane对照试验中央注册库数据库，以识别研究LEV治疗脑肿瘤患者疗效的文章和会议摘要。本荟萃分析纳入了14项研究。在纳入的14项研究中，有两项是随机对照试验。亚组分析表明，LEV的完全缓解率在术后期间为94%，在长期随访期间为84%。我们的结果表明，LEV是治疗脑肿瘤患者的一种相对有效的药物，其疗效在长期随访期间略低于术后期间。有必要进行进一步的随机对照试验。
